Daniel R Calabrese, MD
Pulmonary Disease · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
- Since medical school
- 15 years
- Graduated 2011
Offices
2 locations · University of California San Francisco · 1,780 clinicians in this group
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Calabrese’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
State licence records
1 licence
- Washington MD.MD.60391083Physician And Surgeon License · since 2013 · expires 2014-09-22ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$9,089
Medicare paid this office $9,089 for 58 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 57 | $7,915 | $124 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 51 | $829 | $15 |
Who their Medicare patients are
58 Original Medicare patients in 2024. Average age 66 · Women 38% · Also on Medicaid 40% · Health risk score 3.43. Sicker patients than 9 in 10 peers; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Chronic kidney disease 55% · COPD 53% · Diabetes 50% · Coronary heart disease 40% · Heart failure 36% · Depression 34% · Atrial fibrillation 22%.
The office billed $56,590, Medicare allowed $11,700 and paid $9,089; for 124 services of 4 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 58 | 124 | 66 | 3.43 | $56,590 | $9,089 |
| 2023 | 49 | 55 | 67 | 3.11 | $42,827 | $6,926 |
| 2022 | 42 | 47 | 65 | 3.46 | $35,741 | $5,726 |
| 2021 | 104 | 145 | 66 | 2.98 | $55,320 | $9,055 |
| 2020 | 143 | 248 | 67 | 2.64 | $56,858 | $7,628 |
| 2019 | 220 | 447 | 67 | 2.63 | $100,511 | $13,297 |
| 2018 | 39 | 43 | 67 | 2.18 | $33,421 | $4,374 |
| 2015 | 81 | 85 | 74 | 2.69 | $67,462 | $12,707 |
| 2014 | 29 | 31 | 66 | 3.24 | $24,498 | $4,800 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Long return visit (40+ min) | 48 | $6,764 | $125 |
2022: 1 service
| Long return visit (40+ min) | 41 | $5,637 | $123 |
2021: 3 services
| Long return visit (40+ min) | 57 | $7,871 | $125 |
| Test to measure expiratory airflow and volume | 43 | $313 | $7 |
| Test to examine how well the lungs exchange gases | 24 | $185 | $8 |
2020: 5 services
| Long return visit (40+ min) | 49 | $5,642 | $99 |
| Test to measure expiratory airflow and volume | 96 | $725 | $7 |
| Test to examine how well the lungs exchange gases | 52 | $421 | $8 |
| Test for exercise-induced lung stress | 14 | $290 | $21 |
| Test to determine lung volumes using sensors | 15 | $155 | $10 |
2019: 8 services
| Long return visit (40+ min) | 69 | $7,960 | $95 |
| Test to measure expiratory airflow and volume | 143 | $1,226 | $8 |
| Long return visit (40+ min) | 14 | $1,223 | $87 |
| Test to examine how well the lungs exchange gases | 70 | $570 | $8 |
| Test to determine lung volumes using sensors | 43 | $491 | $11 |
| Test for exercise-induced lung stress | 23 | $477 | $21 |
| Test to determine lung volumes using gas dilution or washout | 26 | $290 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 12 | $142 | $12 |
2018: 2 services
| Long return visit (40+ min) | 22 | $2,468 | $99 |
| Long return visit (40+ min) | 11 | $1,012 | $92 |
2015: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,398 | $179 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,081 | $90 |
2014: 1 service
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,433 | $181 |
Medicaid work
$191 in 2021
Medicaid paid $191 for 33 billed services this clinician did in 2021, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 19 | $103 |
| Diffusing capacity | 14 | $87 |
| 2021 | 33 | 2 | 19 | $191 |
| 2020 | 61 | 2 | 28 | $438 |
| 2019 | 94 | 2 | 26 | $762 |
See the largest Medicaid services in earlier years
2020
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 47 | $357 |
| Diffusing capacity | 14 | $81 |
2019
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 68 | $547 |
| Diffusing capacity | 26 | $215 |
Drugs they prescribed that Part D paid
$7,809
Pharmacies billed $7,809 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 89) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
78 generic and 11 brand-name prescriptions · $7,809 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dapsone | 15 | $390 | $26 |
| Prednisone | 15 | $236 | $16 |
Year by year
| 2024 | 89 | 32 | 0% (0) | 12% | $7,809 |
| 2023 | 34 | 13 | 0% (0) | None | $3,626 |
| 2022 | 22 | 11 | 0% (0) | None | $733 |
| 2021 | 53 | 18 | None | 34% | $7,683 |
| 2020 | 66 | 24 | None | 27% | $12,006 |
| 2019 | 147 | 32 | 0% (0) | 39% | $32,059 |
| 2018 | 47 | 15 | 0% (0) | 43% | $7,400 |
| 2016 | 44 | 14 | 0% (0) | 82% | $11,966 |
| 2015 | 39 | 15 | 0% (0) | 67% | $7,122 |
| 2014 | 157 | 38 | 7% (11) | None | $5,105 |
| 2013 | 189 | 32 | None | 19% | $11,423 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2020: 1 drug
| Spiriva Respimat | 12 | $5,742 | $479 |
2019: 2 drugs
| Wixela Inhub | 17 | $6,102 | $359 |
| Azithromycin | 20 | $493 | $25 |
2018: 1 drug
| Azithromycin | 11 | $304 | $28 |
2016: 2 drugs
| Spiriva | 19 | $7,044 | $371 |
| Advair Diskus | 11 | $4,503 | $409 |
2015: 1 drug
| Invanz | 11 | $3,273 | $298 |
2014: 4 drugs
| Atorvastatin | 11 | $321 | $29 |
| Lisinopril | 18 | $79 | $4 |
| Metoprolol | 13 | $63 | $5 |
| Trazodone | 11 | $55 | $5 |
2013: 4 drugs
| Atorvastatin | 14 | $352 | $25 |
| Lisinopril | 20 | $148 | $7 |
| Metoprolol | 14 | $74 | $5 |
| Trazodone | 12 | $60 | $5 |
Money from drug and device companies
$128 in 2025
| 2025 | 1 | 2 | None | $128 |
| 2022 | 1 | 1 | $3,435 | $3,435 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Kamada | Cytogam | $128 | 2 payments
|
See all 2 published payments
| Kamada | Meals · 2025-05-17 | Cytogam | $24 |
| Kamada | Meals · 2025-04-08 | Cytogam | $103 |
See earlier years (2022)
2022: $3,435
| CSL Behring | Berinert | $3,435 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Kamada Ltd. · The Role of Cmv Igg in Modulating the Lung Injury Immune Response After Lung Transplant · 2025 | Their institution | $307,298 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1659670438
- Licence
- WA MD 60391083Washington MD.MD.60391083: Expired
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Internal medicine (207R00000X); Student in a training program (390200000X)
- Mailing address
- 1959 Ne Pacific St Rm Bb-527, Box 356421, Seattle, WA, 98195
- NPI first listed
- 2011-03-20
- NPI last updated
- 2013-07-16
This is when the NPI record was last certified, not a medical board exam.